Monarch E Trial In High Risk Early Breast Cancer

Rodrigo Arrangoiz MS, MD, FACS, FSSO
  • The addition of abemaciclib to adjuvant endocrine therapy:
    • Was evaluated in the phase 3 monarchE trial:
      • That enrolled patients with high-risk, early-stage breast cancer:
        • With high risk defined as:
          • ≥ 4 axillary nodes or
          • 1 to 3 axillary nodes with:
            • Grade 3 histology
            • A large primary tumor (equal or greater than 5 cm)
            • High Ki67 score:
              • Defined as ≥ 20%
      • At a median 27 months of follow up:
        • The addition of abemaciclib led to statistically significant improvements in:
          • Invasive disease-free survival (IDFS) (HR, 0.70; 95% CI, 0.59-0.82; nominal P < 0.0001)
          • Distant relapse-free survival (DRFS) (HR, 0.69; 95% CI, 0.57-0.83; nominal P < 0.0001)
        • These findings were consistent with those from earlier data analyses
        • A low Ki-67 level was prognostic of better outcome:
          • However, it was not predictive of benefit from abemaciclib in this study
      • Results from a prespecified overall survival (OS) interim analysis were presented at the 2022 San Antonio Breast Cancer Symposium:
        • All patients were no longer receiving abemaciclib at a median follow-up of 42 months
        • Invasive DFS and DRFS benefits were sustained beyond the treatment period
        • OS data remained immature at time of analysis (Table 1.1)

Table 1.1. Efficacy Results From the monarchE Study Presented at SABCS 2022

#Arrangoiz #BreastSurgeon #CancerSurgeon #SurgicalOncologist #MountSinaiMedicalCenter #MSCM #Miami #Mexico #BreastCancer
Unknown's avatar

Published by Rodrigo Arrangoiz MS, MD, FACS, FSSO

My name is Rodrigo Arrangoiz I am a breast surgeon/ thyroid surgeon / parathyroid surgeon / head and neck surgeon / surgical oncologist that works at Center for Advanced Surgical Oncology in Miami, Florida. I was trained as a surgeon at Michigan State University from (2005 to 2010) where I was a chief resident in 2010. My surgical oncology and head and neck training was performed at the Fox Chase Cancer Center in Philadelphia from 2010 to 2012. At the same time I underwent a masters in science (Clinical research for health professionals) at the University of Drexel. Through the International Federation of Head and Neck Societies / Memorial Sloan Kettering Cancer Center I performed a two year head and neck surgery and oncology / endocrine fellowship that ended in 2016. Mi nombre es Rodrigo Arrangoiz, soy cirujano oncólogo / cirujano de tumores de cabeza y cuello / cirujano endocrino que trabaja Center for Advanced Surgical Oncology en Miami, Florida. Fui entrenado como cirujano en Michigan State University (2005 a 2010 ) donde fui jefe de residentes en 2010. Mi formación en oncología quirúrgica y e n tumores de cabeza y cuello se realizó en el Fox Chase Cancer Center en Filadelfia de 2010 a 2012. Al mismo tiempo, me sometí a una maestría en ciencias (investigación clínica para profesionales de la salud) en la Universidad de Drexel. A través de la Federación Internacional de Sociedades de Cabeza y Cuello / Memorial Sloan Kettering Cancer Center realicé una sub especialidad en cirugía de cabeza y cuello / cirugia endocrina de dos años que terminó en 2016.

Leave a comment